References
- Gu XF. Clinical genetic metaboic dieseases. People’s Medical Publishing House; 2015. p. 36–136. (in chinese)
- National Heath Commission of the People’s Republic of China. Regulations on Newborn Screening. 2009. (in chinese)
- Yuskiv N, Potter BK, Stockler S, et al. Nutritional management of phenylalanine hydroxylase (PAH) deficiency in pediatric patients in Canada: a survey of dietitians' current practices. Orphanet J Rare Dis. 2019;14(1):7.
- Gundorova P, Zinchenko RA, Kuznetsova IA, et al. Molecular-genetic causes for the high frequency of phenylketonuria in the population from the North Caucasus. PLoS One. 2018;13(8):e0201489.
- Giżewska M, MacDonald A, Bélanger-Quintana A, et al. Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results. Eur J Pediatr. 2016;175(2):261–272.
- Banta-Wright SA, Press N, Knafl KA, et al. Breastfeeding infants with phenylketonuria in the United States and Canada. Breastfeeding Med. 2014;9(3):142–148.
- Lee YW, Lee DH, Kim ND, et al. Mutation analysis of PAH gene and characterization of a recurrent deletion mutation in Korean patients with phenylketonuria. Exp Mol Med. 2008;40(5):533–540.
- Zhao ZD, Yu J, Yang C, et al. Current status of neonatal phenylketonuria screening in Hainan Province. Mater Child Health Care China. 2013;28:5313–5314.
- Liu N, Huang Q, Li Q, et al. Spectrum of PAH gene variants among a population of Han Chinese patients with phenylketonuria from northern China. BMC Med Genet. 2017;18(1):108.
- Xiang L, Tao J, Deng K, et al. Phenylketonuria incidence in China between 2013 and 2017 based on data from the Chinese newborn screening information system: a descriptive study. BMJ Open. 2019;9(8):e031474.
- Ou YH, Hu XN, Long H, et al. Analysis of neonatal PKU screening results in Qingyuan from 2016 to 2018. Chinese J Birth Health Heredity. 2019;27:77–78.
- Razipour M, Kooshavar D, Alavinejad E, et al. Identification of a novel mutation in the PAH gene in an Iranian phenylketonuria family: A Case Report. Iran J Public Health. 2017;46:560–564.
- Vieira Neto E, Laranjeira F, Quelhas D, et al. Mutation analysis of the PAH gene in phenylketonuria patients from Rio de Janeiro, Southeast Brazil. Mol Genet Genomic Med. 2018;6(4):575–591.
- Zhang X, Chen HX, Li C, et al. Rapid detection of PAH gene mutations in Chinese people. BMC Med Genet. 2019;20(1):135.
- Yu W, He J, Yang X, et al. Characterization of phenylalanine hydroxylase gene mutations in phenylketonuria in Xinjiang of China. Int J Clin Exp Med. 2014;7(11):4406–4412.
- van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.
- Zhou YA, Ma YX, Zhang QB, et al. Mutations of the phenylalanine hydroxylase gene in patients with phenylketonuria in Shanxi, China. Genet Mol Biol. 2012;35(4):709–713.
- Wang WP, Zou L, Wang ZG. Newborn screening, prenatal diagnosis and laboratory Management. People’s Medical Publishing House. 2018. p. 247.
- Guldberg P, Rey F, Zschocke J, et al. A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet. 1998;63(1):71–79.
- Chen T, Xu W, Wu D, et al. Mutational and phenotypic spectrum of phenylalanine hydroxylase deficiency in Zhejiang Province, China. Sci Rep. 2018;8(1):17137.
- Wang T, Ma J, Zhang Q, et al. Expanded newborn screening for inborn errors of metabolism by tandem mass spectrometry in Suzhou, China: disease spectrum, prevalence, genetic characteristics in a Chinese population. Front Genet. 2019;10:1052.
- Li N, He C, Li J, et al. Analysis of the genotype-phenotype correlation in patients with phenylketonuria in mainland China. Sci Rep. 2018;8(1):11251.
- Gu Y, Lu K, Yang G, et al. Mutation spectrum of six genes in Chinese phenylketonuria patients obtained through next-generation sequencing. PLoS One. 2014;9(4):e94100.